How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

doi:10.3164/jcbn.17-62

Paper

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Published Nov 11, 2017 · Kazutoshi Watanabe, Masahiko Tanaka, S. Yuki

Journal of Clinical Biochemistry and Nutrition

Q2 SJR score

169

Citations

8

Influential Citations

Full textSemantic Scholar

Abstract

Edaravone is a low-molecular-weight antioxidant drug targeting peroxyl radicals among many types of reactive oxygen species. Because of its amphiphilicity, it scavenges both lipid- and water-soluble peroxyl radicals by donating an electron to the radical. Thus, it inhibits the oxidation of lipids by scavenging chain-initiating water-soluble peroxyl radicals and chain-carrying lipid peroxyl radicals. In 2001, it was approved in Japan as a drug to treat acute-phase cerebral infarction, and then in 2015 it was approved for amyotrophic lateral sclerosis (ALS). In 2017, the U.S. Food and Drug Administration also approved edaravone for treatment of patients with ALS. Its mechanism of action was inferred to be scavenging of peroxynitrite. In this review, we focus on the radical-scavenging characteristics of edaravone in comparison with some other antioxidants that have been studied in clinical trials, and we summarize its pharmacological action and clinical efficacy in patients with acute cerebral infarction and ALS.

Rigorous Journal

Highly Cited

Study Snapshot

Edaravone effectively treats acute cerebral infarction and ALS by scavenging peroxynitrite, making it a promising antioxidant for these conditions.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Sign up to use Study Snapshot

References

Free Radical

My research career from 1955 to 2000 focused on studying free radicals and molecular ions, with a focus on electronic structure and microwave spectra.

Pulse Radiolysis

Pulse radiolysis is a technique used to study the effects of radiation on water and aqueous solutions, providing insights into chemical reactions and processes.

Development of a novel oral delivery system of edaravone for enhancing bioavailability.

The Novel Oral Delivery System (NODS) significantly enhances the bioavailability of edaravone, making it a promising candidate for use in oxidative stress-associated diseases.

Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration

Edaravone administration effectively reduces oxidative stress in ALS patients, potentially enhancing their functional recovery.

Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone

Edaravone acts as a scavenger of peroxynitrite and lipid peroxyl radicals, potentially benefiting patients with acute brain infarction and amyotrophic lateral sclerosis.

Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse

Edaravone, a free radical scavenger, can delay motor neuron disease progression in a wobbler mouse model, suggesting potential therapeutic benefits for ALS patients.

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Edaravone showed a smaller reduction in ALSFRS-R scores than placebo, but its efficacy for treating ALS was not demonstrated, with similar levels and frequencies of reported adverse events.

Citations

Nanosized Aluminum Metal-Organic Framework Encapsulating Edaravone Drug: Synthesis and Characterization.

Nanoporous aluminum metal-organic framework nanoparticles show potential as effective drug delivery vehicles with 60% encapsulation efficiency and 12% loading capacity.

Oxidative stress and chronic cerebral hypoperfusion: An overview from preclinical rodent models.

Edaravone shows potential in reducing neuronal and vascular damage caused by chronic cerebral hypoperfusion-induced oxidative stress in rodent models.

Therapeutic targeting of the oxidative stress generated by pathological molecular pathways in the neurodegenerative diseases, ALS and Huntington's.

Targeting oxidative stress pathways and redox modulators may offer potential treatments for neurodegenerative diseases like ALS and Huntington's, with edaravone being approved for ALS treatment.

Efficacy and tolerability of celastrol and edaravone in the multiple-hit rat model of infantile spasms

Celastrol effectively reduces infantile spasms in a rat model, but edaravone does not, suggesting NFkB inhibitors may be useful in treating drug-resistant infantile spasms.

The Potential Effects of 2,3,4-Trihydroxybenzophenone on the Transient Cerebral Ischemic Stroke in Male Mice.

THB shows potential in treating transient cerebral ischemic stroke by increasing neurite outgrowth, suppressing oxidative stress, and reducing infarct volume in a mouse model.

Ferroptosis: mechanisms and therapeutic targets

Ferroptosis plays a crucial role in various diseases, and targeting it with therapeutic approaches shows promise for improving human health and disease management.